Published · Aurelis Peptides
KPV and BPC-157 appear in gut research, but the papers below ask different questions. KPV was examined for changes in inflammatory signals in cells and experimental colitis in mice. BPC-157 was examined for healing at a surgically joined section of intestine in rats. Understanding those settings makes the comparison more useful than a broad “gut health” label.
Aurelis lists KPV 10 mg and BPC-157 10 mg. These are separate named entries. Their matching milligram amounts do not make them interchangeable.
KPV vs BPC-157 at a glance
| Comparison | KPV | BPC-157 |
|---|---|---|
| Peptide description in the source | Lys-Pro-Val tripeptide: three amino-acid residues | Gastric pentadecapeptide: fifteen residues |
| Selected study setting | Intestinal and immune cell models; induced colitis in mice | Intestinal anastomosis healing in rats |
| Main question | Inflammatory signalling and peptide uptake | Repair of a surgically joined intestinal segment |
| Measurements | Signalling activity, cytokines and tissue assessment | Tissue assessment and resistance to leakage |
| Aurelis listed content | 10 mg per unit | 10 mg per unit |
The table compares two separate publications. It is not a head-to-head experiment and does not establish which peptide is better. Keep the original model and endpoint attached to each finding.
Why does KPV appear in gut-health searches?
The Dalmasso and colleagues study examined whether a transporter called PepT1 helps KPV enter cells. A transporter is a protein involved in moving substances across a cell membrane. The researchers studied intestinal epithelial cell lines and an immune cell line, alongside two mouse models of induced colitis. Read the original KPV study.
They reported reduced activity in inflammatory signalling pathways and reduced secretion of pro-inflammatory cytokines in the cell experiments. Cytokines are signals used by cells. In the mouse experiments, the authors also reported lower inflammatory measures. These findings explain the connection between KPV and intestinal-inflammation research.
What intestinal question was studied for BPC-157?
The Vuksic and colleagues paper studied ileoileal anastomosis healing in rats. An anastomosis is a surgical connection; here, the researchers joined sections of the small intestine. They assessed the joined tissue visually, under the microscope and through tests of leakage resistance. Read the original BPC-157 study.
The authors reported improved healing measurements in the experimental model, including greater resistance to leakage. This is a repair question with a defined surgical setting. It differs from the inflammatory-signalling question in the KPV paper.
How to compare the papers without losing the detail
Start with four fields: the named peptide, the model, the measured outcome and the comparison group. A reduction in a cell signal and an improvement in tissue leakage resistance are different endpoints. They cannot be put on one scale simply because both involve the intestine.
The studies described here are preclinical experiments, not tests of the offered Aurelis batches or a comparison of outcomes in customers. For a broader repair-related comparison, see BPC-157 vs TB-500; that guide addresses a different research question.
What does 10 mg mean on these entries?
The catalogue amount describes listed content per unit. It is not a concentration, a delivered amount or a use schedule. A liquid concentration would also require a stated volume and reporting basis. Keep these fields separate when comparing specifications.
For either name, request the accepted identity, content basis and selected batch records through the quality-documentation page. A paper explains the material studied in that experiment; the offered batch needs its own matching documents.
Vials, kits and blends are separate specification questions
Aurelis presents both vials and pen-style kits. Confirm the available configuration for the exact entry rather than assuming that every catalogue peptide has every presentation. Images illustrate a format; the enquiry should establish the actual contents.
If you are comparing a blend, request its accepted component identities and amounts. A blend containing KPV or BPC-157 is a separate specification from either standalone entry. Our blend guide retains unresolved details instead of filling them in.
Ask for the specification you need
Include KPV 10 mg or BPC-157 10 mg, preferred presentation, requested quantity and destination in the USA, Canada or Australia. Ask for matching batch documentation and confirmation of current local availability. This gives the team a precise enquiry to answer.
Enquire about KPV or BPC-157, email sales@aurelispeptides.com or explore the research library.
Primary sources
- Dalmasso et al. · Gastroenterology · 2008 — KPV transport and intestinal-inflammation models.
- Vuksic et al. · Surgery Today · 2007 — BPC-157 intestinal-anastomosis experiment in rats.